IntrinsiQ's first IntelliView 360 research study results released

Sep 16 2009

IntrinsiQ, the company improving the quality and understanding of cancer care, today announced the findings of the company’s first IntelliView 360™ research study. The biggest outcome: Oncologists believe they treat lung cancer patients in the maintenance setting three times more often than they actually do.

This study examines the use of maintenance therapy – an option for metastatic cancer patients to incrementally extend survival or improve their quality of life – in treating non-small cell lung cancer (NSCLC). Findings indicate that oncologists predominantly choose aggressive therapy followed by no treatment at all until the disease progresses, despite promising clinical data from maintenance use with drugs such as Alimta and Tarceva.

“The disconnect between attitudes and behavior shows that there is a large, untapped intent to treat with maintenance therapy,” said Jeff Forringer, IntrinsiQ’s president. “This represents a significant opportunity for the company that can figure out how to turn the intent into action. On the other hand, if you are developing a clinical trial for NSCLC, it is critical that you understand how this potential shift in treatment patterns could impact your trial design.”

IntelliView 360, IntrinsiQ’s custom research service behind this report, links oncologist practice information with primary research, to bridge the gap between actual patient treatment and oncologists’ recall in surveys. It is the only reliable conduit to investigate cancer caregivers’ behavior and answer questions of key importance, such as:

• How big is the maintenance opportunity for our drug?
• Are there patients we’re currently missing? What standard-of-care do they currently receive most often?
• If we pursue clinical investigations in other settings, what will be the long-term impact on forecasts? On overall product positioning?
• What clinical proof will convince physicians to treat a certain way?

To address key emerging issues in medical oncology, IntelliView 360 ties physicians’ attitudes, opinions, and views to IntrinsiQ data through a validated panel of medical and hematology oncologists – the same oncologists that use IntrinsiQ’s flagship clinical software, IntelliDose®, to manage chemotherapy treatment. Panel members treat nearly 20,000 unique patients per month and practice in settings ranging from academic medical centers to hospitals to multispecialty private practices.

http://www.intrinsiq.com/